SKB264 binds TROP2 on tumor cells, is internalized, and releases a topoisomerase I–inhibiting payload that causes DNA damage and apoptosis. Cytotoxicity is driven by TROP2-targeted delivery (with possible bystander effect), while DNA topoisomerase I is the intracellular enzymatic target of the payload, not the targeting antigen.